Loss of bone density from Anastrozole is somewhat reversible after treatment

A study by researchers from Queen Mary University of London shows that bone loss that is known to be associated with the use of the breast cancer prevention drug Anastrozole is somewhat reversible, in particular at the lumbar spine, after cessation of treatment.

Anastrozole is a hormone treatment recommended by NICE to prevent breast cancer in high-risk postmenopausal women.

The results, published in the British Journal of Cancer, are from a subset of 1,410 women from the International Breast Cancer Intervention Study (IBIS-II) who examined bone density in women who had undergone anastrozole treatment to complete.

At the seven-year mark, two years after women stopped treatment, the study found that those with weak bones experienced an increase in bone density at the lumbar spine. The elevation did not occur at full hip. The results suggest that reduced bone mineral density as a result of anastrozole treatment improves after discontinuation of anastrozole treatment.

Lead author Ivana Sestak of Queen Mary University in London said: “Overall, the bone loss associated with anastrozole appears to be manageable. Any risk to bone health should be addressed. to measure against the overall efficacy and tolerability of immunosuppressive treatment of high-risk women … discuss in the decision-making process. “

Follow more stories on it Facebook and Twitter

This story was published from a wire group group with no text changes.